GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BioMark Diagnostics BUX.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.45

—

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2026

Revenue

C$59,787

FY2017FY2026

Net income

−C$1.5m

FY2017FY2026

Free cash flow

−C$1.1m

FY2017FY2026

Shareholders' equity

C$331,063

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueC$59,787C$154,220C$163,220C$153,490C$43,933—C$263,283———
Research and developmentC$667,761C$696,012C$650,534C$545,841C$497,773C$118,432C$42,347C$56,430C$58,200C$51,954
Operating income−C$1.5m−C$2.1m−C$1.6m−C$1.9m−C$1.4m−C$1.1m−C$1.2m−C$545,612−C$726,747−C$721,006
Net income−C$1.5m−C$1.9m−C$1.4m−C$1.8m−C$1.5m−C$1.1m−C$1.2m−C$545,612−C$726,747−C$715,424
Diluted earnings per share-0.01-0.02-0.02-0.02-0.02-0.01-0.02-0.01-0.01-0.01

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsC$1.9mC$3.1mC$1.1mC$732,290C$1.5mC$952,939C$637,295C$34,642C$51,746C$39,572
Cash and short-term investments—C$2.5mC$156,750C$72,040C$382,710C$877,680C$611,800C$19,990C$36,630C$17,490
Total liabilitiesC$1.5mC$1.4mC$1.7mC$1.9mC$2.1mC$1.0mC$1.1mC$1.3mC$952,172C$1.1m
Debt—C$160,710C$454,160C$446,470C$750,080C$109,620————
Shareholders' equityC$331,063C$1.7m−C$609,606−C$1.1m−C$635,692−C$79,094−C$439,127−C$1.2m−C$900,426−C$1.1m
Shares outstanding105m105m91m83m78m77m72m65m63m54m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−C$1.1m−C$1.1m−C$982,520−C$914,420−C$1.2m−C$807,300−C$453,785−C$277,838−C$770,417−C$109,549
Capital spending−C$4,234−C$3,530−C$4,390−C$5,300−C$59,201−C$59,201−C$790−C$790−C$1,640−C$1,640
Free cash flow−C$1.1m−C$1.1m−C$986,910−C$919,720−C$1.3m−C$866,501−C$454,575−C$278,628−C$772,057−C$111,189

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueC$7,008C$7,008C$6,916C$6,871C$38,992C$38,990C$38,560C$38,350
Operating income−C$367,043−C$254,633−C$356,346−C$455,210−C$390,685−C$622,670−C$320,580−C$589,970
Net income−C$364,306−C$199,470−C$380,322−C$481,393−C$416,010−C$421,930−C$334,770−C$547,310
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.01
Cash from operations—————−C$1.0m——
Total assetsC$2.2mC$1.9mC$2.1mC$1.9mC$2.7mC$3.1mC$876,630C$877,840
Cash and short-term investments—————C$2.5mC$88,580C$34,650
Debt—————C$160,710C$454,160C$454,160
Shareholders' equityC$571,207C$331,063C$508,033C$863,465C$1.3mC$1.7m−C$1.1m−C$1.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-27.0%—29.8%
Operating income-9.0%6.1%0.8%
Net income-7.1%6.2%0.5%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-1679.6%-1345.3%——
Net margin-1590.8%-1257.6%——

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-32.0-25.6-12.7-11.5-11.8-18.9-8.9-17.7-2.5-4.7
Price to sales—320.3111.4138.4390.5—41.2———

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.